The pharmaceutical firm said it is confident the jabs for cancer could be ready by the end of the decade
There could be vaccines for a wide range of conditions - including cancer by 2030 - according to Moderna’s chief executive.
READ MORE: Footage captures moment audience member 'screams' over I Will Always Love You at Bodyguard Palace Theatre show before police show up “I think we will have mRNA-based therapies for rare diseases that were previously undruggable, and I think that 10 years from now, we will be approaching a world where you truly can identify the genetic cause of a disease and, with relative simplicity, go and edit that out and repair it using mRNA-based technology,” Dr Burton added.
This involves identifying protein fragments on the surface of cancer cells that are not present on healthy cells – and which are most likely to trigger an immune response – and then creating pieces of mRNA that will instruct the body on how to manufacture them.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
North Sea Oil Production Could Fall By 80% By 2030 | OilPrice.comInvestments in the North Sea have significantly decreased, which may lead to an 80% oil production decrease by 2030 and push the UK to rely on foreign fossil fuels for its energy needs.
Weiterlesen »
Nasal SARS-CoV-2 vaccine outperforms existing vaccines in preclinical trialNasal SARS-CoV-2 vaccine outperforms existing vaccines in preclinical trial Coronavirus Disease COVID SARSCoV2 Vaccine Mucosal NatureMicrobiol ChariteBerlin FU_Berlin HumboldtUni PEI_Germany
Weiterlesen »
RNAdegformer: accurate prediction of mRNA degradation at nucleotide resolution with deep learningAbstract. Messenger RNA-based therapeutics have shown tremendous potential, as demonstrated by the rapid development of messenger RNA based vaccines for COVID-1
Weiterlesen »
Researchers find an antibody that targets omicron and other SARS-CoV-2 variantsA team led by researchers at Weill Cornell Medicine, the University of Wisconsin-Madison; Scripps Research and the University of Chicago has identified an antibody that appears to block infection by all dominant variants of the virus that causes COVID-19, including Omicron, the most recent. Their discovery could lead to more potent vaccines and new antibody-based treatments.
Weiterlesen »
Ethnic minority representation in UK COVID-19 trials: systematic review and meta-analysis - BMC MedicineBackground The COVID-19 pandemic has highlighted health disparities affecting ethnic minority communities. There is growing concern about the lack of diversity in clinical trials. This study aimed to assess the representation of ethnic groups in UK-based COVID-19 randomised controlled trials (RCTs). Methods A systematic review and meta-analysis were undertaken. A search strategy was developed for MEDLINE (Ovid) and Google Scholar (1st January 2020–4th May 2022). Prospective COVID-19 RCTs for vaccines or therapeutics that reported UK data separately with a minimum of 50 participants were eligible. Search results were independently screened, and data extracted into proforma. Percentage of ethnic groups at all trial stages was mapped against Office of National Statistics (ONS) statistics. Post hoc DerSimonian-Laird random-effects meta-analysis of percentages and a meta-regression assessing recruitment over time were conducted. Due to the nature of the review question, risk of bias was not assessed. Data analysis was conducted in Stata v17.0. A protocol was registered (PROSPERO CRD42021244185). Results In total, 5319 articles were identified; 30 studies were included, with 118,912 participants. Enrolment to trials was the only stage consistently reported (17 trials). Meta-analysis showed significant heterogeneity across studies, in relation to census-expected proportions at study enrolment. All ethnic groups, apart from Other (1.7% [95% CI 1.1–2.8%] vs ONS 1%) were represented to a lesser extent than ONS statistics, most marked in Black (1% [0.6–1.5%] vs 3.3%) and Asian (5.8% [4.4–7.6%] vs 7.5%) groups, but also apparent in White (84.8% [81.6–87.5%] vs 86%) and Mixed 1.6% [1.2–2.1%] vs 2.2%) groups. Meta-regression showed recruitment of Black participants increased over time (p = 0.009). Conclusions Asian, Black and Mixed ethnic groups are under-represented or incorrectly classified in UK COVID-19 RCTs. Reporting by ethnicity lacks consistency and transparency. Under-re
Weiterlesen »
UK police ready to bring back live facial recognitionReport says software has improved, but thousands could still end up falsely ID'd, argue privacy advocates
Weiterlesen »